What are the side effects of fruquintinib and how should they be monitored and managed?

Fruquintinib Side Effects

Fruquintinib causes grade ≥3 adverse events in 63% of patients, with the most common severe toxicities being hypertension (14%), asthenia (8%), and hand-foot syndrome (6%), requiring proactive monitoring and dose modifications to maintain treatment efficacy while preserving quality of life. 1

Overall Adverse Event Profile

Based on the pivotal FRESCO-2 trial and FDA labeling, fruquintinib demonstrates a predictable toxicity pattern consistent with VEGFR inhibition:

• Any grade adverse events: 86.7-100% of patients 2, 3
• Grade ≥3 adverse events: 63% (compared to 50% with placebo) 1, 4
• Treatment discontinuation due to toxicity: Only 20% 1

This relatively low discontinuation rate despite high overall adverse event frequency indicates that most toxicities are manageable with appropriate interventions.

Most Common Severe Adverse Events (Grade ≥3)

Hypertension (14%)

• Median time to onset: 10 days 5
• Management approach:
  • Control blood pressure before initiating fruquintinib 2
  • Monitor blood pressure regularly during treatment
  • Initiate or intensify antihypertensive medications
  • Withhold, dose reduce, or permanently discontinue based on severity 2

Hand-Foot Syndrome/Palmar-Plantar Erythrodysesthesia (6-10.8%)

• Median time to onset: 21 days 5
• Incidence: Occurs in 49.3% at any grade, 10.8% grade ≥3 5
• Management: Withhold fruquintinib based on severity; dose reduction may be necessary 2

Asthenia/Fatigue (8%)

• Common debilitating symptom requiring dose modification 1, 4

Proteinuria (3.2% grade ≥3)

• Median time to onset: 20 days 5
• Incidence: 42.1% at any grade 5
• Management:
  • Monitor urine protein regularly
  • Permanently discontinue for nephrotic syndrome 2

Additional Clinically Significant Toxicities

Hemorrhagic Events

• Closely monitor patients at risk for bleeding
• Withhold, reduce dose, or permanently discontinue based on severity and persistence 2

Hepatotoxicity

• Monitor liver function tests before starting and periodically during treatment
• Withhold, reduce dose, or permanently discontinue based on severity 2
• Grade ≥3 AST increase: 3.6%; ALT increase: 2.2% 2

Gastrointestinal Perforation

• Monitor periodically for signs/symptoms
• Permanently discontinue if GI perforation or fistula develops 2

Infections

• Do not start fruquintinib in patients with active infections
• Withhold during active infections 2

Posterior Reversible Encephalopathy Syndrome (PRES)

• Immediately discontinue if suspected and confirm via MRI 2

Arterial Thromboembolic Events

• Carefully consider initiation in patients with recent thromboembolic history
• Discontinue if arterial thromboembolism develops 2

Laboratory Abnormalities

Most common grade ≥3 laboratory changes 2:

• Creatinine increased: 0.7%
• Urate increased: 26%
• Hemoglobin decreased: 0.7%
• Platelets decreased: 3.6%

Notably, post-marketing surveillance has identified additional signals not prominently featured in initial labeling 6:

• Bone marrow suppression (ROR = 11.17)
• Peripheral neuropathy (ROR = 4.24)
• Dehydration (ROR = 3.98)

Surgical Considerations

Impaired Wound Healing

• Withhold fruquintinib for 2 weeks before major surgery
• Do not administer for at least 2 weeks following major surgery until adequate wound healing
• Safety of resumption after wound healing complications has not been established 2

Special Populations and Dose Modifications

Elderly Patients (≥65 years)

For elderly patients with reduced tolerance, a dose-escalation strategy may be considered 7:

• Start at 3 mg/day
• Escalate to 4 mg/day in Week 2 if tolerated
• Escalate to 5 mg/day in Week 3 if tolerated
• This approach resulted in 51.7% tolerating 4 mg/day with only 13.8% discontinuing due to adverse events

Hepatic Impairment

• No adjustment needed: Mild hepatic impairment
• Not sufficiently studied: Moderate hepatic impairment
• Not recommended: Severe hepatic impairment 2

Critical Warnings

Embryo-Fetal Toxicity

• Can cause fetal harm based on animal studies showing teratogenicity at 0.2 times the clinical dose 2
• Verify pregnancy status before initiating
• Use effective contraception during treatment and for 2 weeks after last dose
• Do not breastfeed during treatment and for 2 weeks after last dose 2

Allergic Reactions

• Contains FD&C Yellow No. 5 (tartrazine) and No. 6 (sunset yellow FCF), which may cause allergic reactions including bronchial asthma in susceptible patients 2

Drug Interactions

Avoid strong CYP3A inducers (e.g., rifampin, phenytoin, carbamazepine) as they decrease fruquintinib exposure and may reduce efficacy 2

Clinical Context

The toxicity profile is manageable and consistent with other VEGFR inhibitors, but requires vigilant monitoring. The fact that only 20% of patients discontinued treatment despite 63% experiencing grade ≥3 events demonstrates that with appropriate dose modifications and supportive care, most patients can continue therapy and derive the significant survival benefit (median OS 7.4 vs 4.8 months) 1, 4.